Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women

Authors: Jin-lu Shan, Nan Dai, Xue-qin Yang, Cheng-yuan Qian, Zhen-zhou Yang, Feng Jin, Mengxia Li, Dong Wang

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Vitamin D plays a central role in cellular proliferation, apoptosis induction, and tumor growth suppression. The vitamin D receptor (VDR) is a crucial mediator for the cellular effects of vitamin D. A series of epidemiological studies have examined the association between the VDR FokI polymorphism and breast cancer risk, but the findings remain inconclusive. Fifteen eligible case–control studies involving 15,681 cancer cases and 20,632 control subjects were identified through searching PubMed, Embase, and Web of Science. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the association. Heterogeneity across studies was examined with the chi-square-based Q test and the I 2 index. Begg’s and Egger’s test were also performed to determine publication bias. All statistical data were analyzed by STATA software. The combined estimates did not show significant risks correlated with the FokI polymorphism. However, we found an increased risk in the subgroup analysis by source of control (OR = 1.11, 95 % CI = 1.01–1.22; heterogeneity test: P = 0.116, I 2 = 0.0 % for ff vs FF; OR = 1.10, 95 % CI = 1.01–1.21; heterogeneity test: P = 0.832, I 2 = 0.0 % for ff vs Ff + FF). This meta-analysis suggests that the presence of FokI polymorphism may contribute to the risk of breast cancer in Caucasians.
Literature
1.
Uitterlinden AG et al. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56.PubMedCrossRef
2.
Bertone-Johnson ER et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1991–7.PubMedCrossRef
3.
Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.CrossRef
4.
Janowsky EC et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999;2(3):283–91.PubMedCrossRef
5.
Lowe LC et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41(8):1164–9.PubMedCrossRef
6.
Jensen SS et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15(8):1370–80.PubMed
7.
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.PubMedCrossRef
8.
Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989;1(8631):188–91.PubMedCrossRef
9.
Hansen CM et al. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 2001;6:D820–48.PubMedCrossRef
10.
Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003;61(7):227–38.PubMedCrossRef
11.
Polly P et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem. 1996;60(3):322–33.PubMedCrossRef
12.
Liu M et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142–53.PubMedCrossRef
13.
Polly P et al. 1 alpha,25-dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling. J Cell Biochem. 1997;67(3):287–96.PubMedCrossRef
14.
Berger U et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988;67(3):607–13.PubMedCrossRef
15.
Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1427–37.PubMedCrossRef
16.
Barroso E et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer. 2008;8:385.PubMedCentralPubMedCrossRef
17.
Chen WY et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2335–9.PubMedCrossRef
18.
Gapska P et al. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Res Treat. 2009;115(3):629–33.PubMedCrossRef
19.
Sinotte M et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer. 2008;15(4):975–83.PubMedCentralPubMedCrossRef
20.
Anderson LN et al. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1708–17.PubMedCrossRef
21.
Curran JE et al. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83(6):723–6.PubMedCrossRef
22.
Guy M et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10(16):5472–81.PubMedCrossRef
23.
John EM et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166(12):1409–19.PubMedCrossRef
24.
25.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
26.
27.
28.
McCullough ML et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007;9(1):R9.PubMedCentralPubMedCrossRef
29.
30.
McKay JD et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(1):297–305.PubMedCrossRef
31.
Engel LS et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1856–67.PubMedCentralPubMedCrossRef
32.
Rollison DE et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S.A. Breast Cancer Res Treat. 2012;132(2):683–91.PubMedCentralPubMedCrossRef
33.
Fuhrman BJ et al. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013;33(2):543–51.PubMedCentralPubMed
34.
Mishra DK et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013;8(3):e57967.PubMedCentralPubMedCrossRef
35.
Shahbazi S et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef
36.
Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. Mol Cell Biochem. 2003;253(1–2):247–54.PubMedCrossRef
37.
Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S–4S.PubMed
38.
39.
Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12(6):915–21.PubMedCrossRef
40.
Raimondi S et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170–80.PubMedCrossRef
41.
Tang C et al. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117(2):391–9.PubMedCrossRef
42.
Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120(1):211–6.PubMedCrossRef
43.
Thakkinstian A et al. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291–306.PubMedCrossRef
Metadata
Title
FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women
Authors
Jin-lu Shan
Nan Dai
Xue-qin Yang
Cheng-yuan Qian
Zhen-zhou Yang
Feng Jin
Mengxia Li
Dong Wang
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1462-z

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

Research Article

Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell

Research Article

RETRACTED ARTICLE: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1

Research Article

Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis

Research Article

Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis

Research Article

Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits